SARS-CoV-2 replicase polyprotein with Molnupiravir in the RNA template strand, molecular model. The image shows the replicase polyprotein (orange), the nonstructural protein 8 (blue), the non-structural protein 7 (cyan), the template RNA with Molnupiravir (green) and the product RNA (pink). As of 2021, Molnupiravir is an antiviral drug candidate currently in phase III trials for the treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA mutations and impairs SARS-CoV-2 replication in animal models and in humans.